European Society of Cardiology: cardiovascular disease statistics 2021: Executive Summary.

Cardiovascular disease European Society of Cardiology Health infrastructure Morbidity Mortality Risk factors Service provision Statistics

Journal

European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796

Informations de publication

Date de publication:
06 06 2022
Historique:
received: 13 09 2021
accepted: 16 12 2021
pubmed: 1 5 2022
medline: 9 6 2022
entrez: 30 4 2022
Statut: ppublish

Résumé

This report from the European Society of Cardiology (ESC) Atlas Project updates and expands upon the widely cited 2019 report in presenting cardiovascular disease (CVD) statistics for the 57 ESC member countries. Statistics pertaining to 2019, or the latest available year, are presented. Data sources include the World Health Organization, the Institute for Health Metrics and Evaluation, the World Bank, and novel ESC sponsored data on human and capital infrastructure and cardiovascular healthcare delivery. New material in this report includes sociodemographic and environmental determinants of CVD, rheumatic heart disease, out-of-hospital cardiac arrest, leftsided valvular heart disease, the advocacy potential of these CVD statistics, and progress towards World Health Organization (WHO) 2025 targets for non-communicable diseases. Salient observations in this report: (i) Females born in ESC member countries in 2018 are expected to live 80.8 years and males 74.8 years. Life expectancy is longer in high income (81.6 years) compared with middle-income (74.2 years) countries. (ii) In 2018, high-income countries spent, on average, four times more on healthcare than middle-income countries. (iii) The median PM2.5 concentrations in 2019 were over twice as high in middle-income ESC member countries compared with high-income countries and exceeded the EU air quality standard in 14 countries, all middle-income. (iv) In 2016, more than one in five adults across the ESC member countries were obese with similar prevalence in high and low-income countries. The prevalence of obesity has more than doubled over the past 35 years. (v) The burden of CVD falls hardest on middle-income ESC member countries where estimated incidence rates are ∼30% higher compared with high-income countries. This is reflected in disability-adjusted life years due to CVD which are nearly four times as high in middle-income compared with high-income countries. (vi) The incidence of calcific aortic valve disease has increased seven-fold during the last 30 years, with age-standardized rates four times as high in high-income compared with middle-income countries. (vii) Although the total number of CVD deaths across all countries far exceeds the number of cancer deaths for both sexes, there are 15 ESC member countries in which cancer accounts for more deaths than CVD in males and five-member countries in which cancer accounts for more deaths than CVD in females. (viii) The under-resourced status of middle-income countries is associated with a severe procedural deficit compared with high-income countries in terms of coronary intervention, ablation procedures, device implantation, and cardiac surgical procedures. Risk factors and unhealthy behaviours are potentially reversible, and this provides a huge opportunity to address the health inequalities across ESC member countries that are highlighted in this report. It seems clear, however, that efforts to seize this opportunity are falling short and present evidence suggests that most of the WHO NCD targets for 2025 are unlikely to be met across ESC member countries.

Identifiants

pubmed: 35488372
pii: 6576206
doi: 10.1093/ehjqcco/qcac014
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

377-382

Informations de copyright

© The European Society of Cardiology 2022.

Auteurs

Adam Timmis (A)

William Harvey Research Institute, Queen Mary University London, London, UK.

Panos Vardas (P)

Hygeia Hospitals Group, HHG, Athens, Greece.
European Heart Agency, European Society of Cardiology, Brussels, Belgium.

Nick Townsend (N)

Department for Health, University of Bath, Bath, UK.

Aleksandra Torbica (A)

Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy.

Hugo Katus (H)

Department of Internal Medicine and Cardiology, University of Heidelberg, Heidelberg, Germany.

Delphine De Smedt (D)

Department of Public Health, Ghent University, Ghent, Belgium.

Chris P Gale (CP)

Medical Research Council Bioinformatics Centre, Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Aldo P Maggioni (AP)

Research Center of Italian Association of Hospital Cardiologists (ANMCO), Florence, Italy.

Steffen E Petersen (SE)

William Harvey Research Institute, Queen Mary University London, London, UK.

Radu Huculeci (R)

European Heart Agency, European Society of Cardiology, Brussels, Belgium.

Dzianis Kazakiewicz (D)

European Heart Agency, European Society of Cardiology, Brussels, Belgium.

Victor de Benito Rubio (VB)

European Heart Agency, European Society of Cardiology, Brussels, Belgium.

Barbara Ignatiuk (B)

Division of Cardiology, Ospedali Riuniti Padova Sud, Monselice, Italy.

Zahra Raisi-Estabragh (Z)

William Harvey Research Institute, Queen Mary University London, London, UK.

Agnieszka Pawlak (A)

Mossakowski Medical Research Centre Polish Academy of Sciences, Warsaw, Poland.

Efstratios Karagiannidis (E)

First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Roderick Treskes (R)

Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.

Dan Gaita (D)

Universitatea de Medicina si Farmacie Victor Babes, Institutul de Boli Cardiovasculare, Timisoara, Romania.

John F Beltrame (JF)

University of Adelaide, Central Adelaide Local Health Network, Basil Hetzel Institute, Adelaide, Australia.

Alex McConnachie (A)

Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.

Isabel Bardinet (I)

European Society of Cardiology, Sophia Antipolis, France.

Ian Graham (I)

Tallaght University Hospital, Dublin, Ireland.

Marcus Flather (M)

Norwich Medical School, University of East Anglia, Norwich, UK.

Perry Elliott (P)

Institute of Cardiovascular Science, University College London, London, UK.

Elias A Mossialos (EA)

Department of Health Policy, London School of Economics, London, UK.

Franz Weidinger (F)

Department of Internal Medicine and Cardiology, Klinik Landstrasse, Vienna, Austria.

Stephan Achenbach (S)

Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH